This registry will provide information about the efficacy and safety of cangrelor in a very high-risk group of patients with acute myocardial infarction undergoing PCI. It will not only include patients with cardiogenic shock, but a variety of patients not able to swallow tablets, such as those after CPR and/or with invasive or non-invasive ventilation. Therefore it will provide information about the use of cangrelor beyond the current knowledge.
Who can participate
Age range
18 Years
Sex
ALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion Criteria:
* Age ≥18 years
* Acute Myocardial infarction (NSTEMI or STEMI)
* PCI with stent implantation
* Treatment with cangrelor during index procedure
* At least one of the following criteria:
* CPR prior to PCI
* Cardiogenic shock
* Heart failure with the need for mechanical or non-invasive ventila-tion
Exclusion Criteria:
No explicit medical exclusion criteria are stated to avoid selection bias.
Questions worth asking your doctor
Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.
1This trial studied cangrelor specifically in heart attack patients who needed CPR, were on a ventilator, or were in cardiogenic shock — if I'm in one of those situations, is cangrelor something my care team would consider using during my procedure?
2The trial measured definite stent thrombosis and recurrent heart attacks as its main outcomes — what did the results actually show, and does that change how my doctor might approach my treatment?
3Since this trial is listed as 'Phase NA,' it seems to be studying a drug already approved but in a very specific high-risk group — how does that affect what we know about the safety and effectiveness of cangrelor for someone in my condition?
4Cangrelor is given intravenously during the procedure, unlike oral blood thinners — can my doctor walk me through how that might fit into my care plan during and after my heart procedure?
5Given that this trial is now completed, has the data been published or presented anywhere, and should I be asking my interventional cardiologist whether those findings are already influencing how they treat patients like me?
Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.
Questions for the trial coordinator
The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.
1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?
A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.
What they're measuring
1
Definite stent thrombosis
Timeframe: from procedure for index MI up to 48 hours
2
Recurrent myocardial infarction
Timeframe: from procedure for index MI up to 48 hours
Trial details
NCT IDNCT04611607
SponsorIHF GmbH - Institut für Herzinfarktforschung